245 related articles for article (PubMed ID: 28888219)
1. Factor Xa inhibition by rivaroxaban in the trough steady state can significantly reduce thrombin generation.
Horinaka S; Sugawara R; Yonezawa Y; Ishimitsu T
Br J Clin Pharmacol; 2018 Jan; 84(1):79-87. PubMed ID: 28888219
[TBL] [Abstract][Full Text] [Related]
2. Clinical evaluation of laboratory methods to monitor exposure of rivaroxaban at trough and peak in patients with atrial fibrillation.
Al-Aieshy F; Malmström RE; Antovic J; Pohanka A; Rönquist-Nii Y; Berndtsson M; Al-Khalili F; Skeppholm M
Eur J Clin Pharmacol; 2016 Jun; 72(6):671-9. PubMed ID: 27066956
[TBL] [Abstract][Full Text] [Related]
3. Intra- and inter- individual rivaroxaban concentrations and potential bleeding risk in patients with atrial fibrillation.
Miklič M; Mavri A; Vene N; Söderblom L; Božič-Mijovski M; Pohanka A; Antovic J; Malmström RE
Eur J Clin Pharmacol; 2019 Aug; 75(8):1069-1075. PubMed ID: 31139866
[TBL] [Abstract][Full Text] [Related]
4. [Evaluation of oral anticoagulation with rivaroxaban, in patients with new onset non valvular atrial fibrillation].
Neira V; Corbalán R; Pereira J; Panes O; Garayar B; Aizman A; Llevaneras S; Villarroel L
Rev Med Chil; 2016 Sep; 144(9):1103-1111. PubMed ID: 28060970
[TBL] [Abstract][Full Text] [Related]
5. Assessment of trough rivaroxaban concentrations on markers of coagulation activation in nonvalvular atrial fibrillation population.
Kitagawa F; Ishii J; Hiramitsu S; Takahashi H; Okuyama R; Kawai H; Muramatsu T; Harada M; Motoyama S; Naruse H; Matsui S; Sarai M; Hayashi M; Watanabe E; Izawa H; Ozaki Y
Heart Vessels; 2017 May; 32(5):609-617. PubMed ID: 27796530
[TBL] [Abstract][Full Text] [Related]
6. Performance of coagulation tests in patients on therapeutic doses of rivaroxaban. A cross-sectional pharmacodynamic study based on peak and trough plasma levels.
Francart SJ; Hawes EM; Deal AM; Adcock DM; Gosselin R; Jeanneret C; Friedman KD; Moll S
Thromb Haemost; 2014 Jun; 111(6):1133-40. PubMed ID: 24401946
[TBL] [Abstract][Full Text] [Related]
7. Factor Xa inhibitors in clinical practice: Comparison of pharmacokinetic profiles.
Goto E; Horinaka S; Ishimitsu T; Kato T
Drug Metab Pharmacokinet; 2020 Feb; 35(1):151-159. PubMed ID: 32007354
[TBL] [Abstract][Full Text] [Related]
8. Dabigatran but not rivaroxaban or apixaban treatment decreases fibrinolytic resistance in patients with atrial fibrillation.
Semeraro F; Incampo F; Ammollo CT; Dellanoce C; Paoletti O; Testa S; Colucci M
Thromb Res; 2016 Feb; 138():22-29. PubMed ID: 26826504
[TBL] [Abstract][Full Text] [Related]
9. Monitoring the roles of prothrombin activation fragment 1 and 2 (F1 + 2) in patients with atrial fibrillation receiving rivaroxaban and apixaban.
Ueno EI; Fujibayashi K; Sawaguchi J; Yasuda Y; Takano S; Fujioka N; Kawai Y; Fujita H; Tanaka Y; Kajinami K
J Thromb Thrombolysis; 2020 Aug; 50(2):371-379. PubMed ID: 32166540
[TBL] [Abstract][Full Text] [Related]
10. Anti-Xa activity in oral factor Xa inhibitor-treated patients with atrial fibrillation and a higher risk of bleeding: a pilot study.
Samoš M; Bolek T; Stančiaková L; Škorňová I; Bánovčin P; Kovář F; Staško J; Galajda P; Kubisz P; Mokáň M
Blood Coagul Fibrinolysis; 2018 Jun; 29(4):369-373. PubMed ID: 29538002
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of global laboratory methods and establishing on-therapy ranges for monitoring apixaban and rivaroxaban: Experience at a single institution.
Park SH; Seo YH; Park PW; Kim KH; Seo JY; Lee HT; Kwoun WJ; Ahn JY
J Clin Lab Anal; 2019 Jun; 33(5):e22869. PubMed ID: 30860622
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the Correlation Between Coagulation Indices and Rivaroxaban Concentrations.
Wu T; Wu S; Li M; Zhang J
Ann Pharmacother; 2024 Jan; 58(1):28-36. PubMed ID: 37125735
[TBL] [Abstract][Full Text] [Related]
13. Accuracy and consistency of anti-Xa activity measurement for determination of rivaroxaban plasma levels.
Studt JD; Alberio L; Angelillo-Scherrer A; Asmis LM; Fontana P; Korte W; Mendez A; Schmid P; Stricker H; Tsakiris DA; Wuillemin WA; Nagler M
J Thromb Haemost; 2017 Aug; 15(8):1576-1583. PubMed ID: 28574652
[TBL] [Abstract][Full Text] [Related]
14. Effect of rivaroxaban on prothrombin fragment 1+2 compared with warfarin in patients with acute cardioembolic stroke: Insight from its serial measurement.
Hagii J; Tomita H; Metoki N; Tamai Y; Saito S; Shiroto H; Hitomi H; Kamada T; Seino S; Takahashi K; Sasaki S; Yasujima M; Okumura K
Thromb Res; 2016 Dec; 148():9-14. PubMed ID: 27764730
[TBL] [Abstract][Full Text] [Related]
15. Anti-coagulation assessment with prothrombin time and anti-Xa assays in real-world patients on treatment with rivaroxaban.
Königsbrügge O; Quehenberger P; Belik S; Weigel G; Seger C; Griesmacher A; Pabinger I; Ay C
Ann Hematol; 2015 Sep; 94(9):1463-71. PubMed ID: 26025632
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of a Heparin-Calibrated Antifactor Xa Assay for Measuring the Anticoagulant Effect of Oral Direct Xa Inhibitors.
Beyer J; Trujillo T; Fisher S; Ko A; Lind SE; Kiser TH
Clin Appl Thromb Hemost; 2016 Jul; 22(5):423-8. PubMed ID: 26842561
[TBL] [Abstract][Full Text] [Related]
17. Impact of rivaroxaban compared with warfarin on the coagulation status in Japanese patients with non-valvular atrial fibrillation: a preliminary analysis of the prothrombin fragment 1+2 levels.
Tajiri K; Sato A; Harunari T; Shimojo N; Yamaguchi I; Aonuma K
J Cardiol; 2015 Mar; 65(3):191-6. PubMed ID: 25192595
[TBL] [Abstract][Full Text] [Related]
18. Multianalyte Determination of NOACs Using LC-MS/MS and Comparison with Functional Coagulation Assays.
Slavik L; Lukes J; Friedecky D; Zhanelova M; Nemcova M; Ulehlova J; Prochazkova J; Hlusi A; Palova M; Vaclavik J
Clin Lab; 2018 Oct; 64(10):1611-1621. PubMed ID: 30336535
[TBL] [Abstract][Full Text] [Related]
19. Does atorvastatin therapy change the anti-Xa activity in xabans-treated patients with atrial fibrillation?
Škorňová I; Samoš M; Bolek T; Stančiaková L; Vádelová Ľ; Galajda P; Staško J; Kubisz P; Mokáň M
Pharmacol Res Perspect; 2021 May; 9(3):e00730. PubMed ID: 33984191
[TBL] [Abstract][Full Text] [Related]
20. Anti-Xa Oral Anticoagulant Plasma Concentration Assay in Real Life: Rivaroxaban and Apixaban Quantification in Emergency With LMWH Calibrator.
Billoir P; Barbay V; Joly LM; Fresel M; Chrétien MH; Le Cam Duchez V
Ann Pharmacother; 2019 Apr; 53(4):341-347. PubMed ID: 30378443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]